In vitro |
CCG-1423 selectively inhibits SRF-mediated transcription activated by Rho pathway signaling, and specifically inhibits LPA-stimulated DNA synthesis. CCG-1423 also selectively inhibits the proliferation of RhoC-overexpressing melanoma cells (A375M2 and SK-Mel-147), and strongly suppresses the Rho-dependent invasion by PC-3 cells. [1] CCG-1423 in combination with LY294002 enhances differentiation of mouse embryonic stem cells into intermediate mesoderm through BMP7-positive cells. [2] In H9c2 cells, CCG-1423 inhibits MRTF nuclear localization, and completely blocks STARS proximal reporter activity. [3] CCG-1423, as a Rho/MRTF/SRF pathway inhibitor, also represses both matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. [4]
|